| scholarly article | Q13442814 |
| P50 | author | Christopher Southan | Q28133217 |
| P2093 | author name string | Colin Dingwall | |
| Ishrut Hussain | |||
| David Powell | |||
| Conrad Chapman | |||
| Gary Christie | |||
| David G. Tew | |||
| David L. Simmons | |||
| David R. Howlett | |||
| Dominic M. Ryan | |||
| Frank S. Walsh | |||
| Israel S. Gloger | |||
| Kay E. Murphy | |||
| Thomas D. Meek | |||
| Trudi S. Smith | |||
| P433 | issue | 6 | |
| P921 | main subject | cell biology | Q7141 |
| P304 | page(s) | 419-427 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Molecular and Cellular Neuroscience | Q6895985 |
| P1476 | title | Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase | |
| P478 | volume | 14 |
| Q40859157 | A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta -secretase |
| Q87944358 | A gender dimorphism in up-regulation of BACE1 gene expression in schizophrenia |
| Q34286129 | A genomic perspective on human proteases |
| Q33953223 | A genomic perspective on human proteases as drug targets |
| Q40851871 | A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases abeta 42 generation in human cells |
| Q22251083 | A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline |
| Q33877903 | A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease |
| Q28540639 | A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug |
| Q90381031 | A novel two-photon ratiometric fluorescent probe for imaging and sensing of BACE1 in different regions of AD mouse brain |
| Q33897528 | A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease |
| Q42177453 | A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. |
| Q40698640 | A series of C-terminal amino alcohol dipeptide A beta inhibitors |
| Q31816631 | A splice variant of beta-secretase deficient in the amyloidogenic processing of the amyloid precursor protein |
| Q28661086 | A tale of two drug targets: the evolutionary history of BACE1 and BACE2 |
| Q36674481 | A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: are we progressing toward therapy? |
| Q30888160 | A yeast genetic assay for caspase cleavage of the amyloid-beta precursor protein. |
| Q90580004 | AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages |
| Q48143467 | ADAM10 and BACE1 are localized to synaptic vesicles |
| Q35019451 | Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. |
| Q34072320 | Abeta-generating enzymes: recent advances in beta- and gamma-secretase research |
| Q33954924 | Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression. |
| Q34651971 | Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease |
| Q36663043 | Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit? |
| Q37137534 | Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice |
| Q48366230 | Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. |
| Q38743102 | Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence |
| Q35069720 | Alzheimer vaccine: amyloid-beta on trial. |
| Q36894385 | Alzheimer's disease and mild cognitive impairment |
| Q37671455 | Alzheimer's disease and the amyloid-beta peptide |
| Q36016766 | Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme |
| Q53235986 | Alzheimer's disease. Closing in on gamma-secretase. |
| Q34105788 | Alzheimer's disease: a dysfunction of the amyloid precursor protein(1). |
| Q34976291 | Alzheimer's disease: beta-Amyloid protein and tau. |
| Q37785311 | Alzheimer's secretases regulate voltage-gated sodium channels |
| Q26750249 | Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging |
| Q38006665 | Amyloid and Alzheimer's disease: inside and out. |
| Q24633400 | Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients |
| Q34208401 | Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease |
| Q37427458 | Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors |
| Q53240567 | Amyloid precursor protein beta-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. |
| Q36038732 | Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation |
| Q48306498 | Amyloid β-Protein Stimulates the Expression of Urokinase-type Plasminogen Activator (uPA) and Its Receptor (uPAR) in Human Cerebrovascular Smooth Muscle Cells |
| Q35112198 | Amyloid, Presenilins, and Alzheimer’s Disease |
| Q35746174 | Amyloid-β Peptide Exacerbates the Memory Deficit Caused by Amyloid Precursor Protein Loss-of-Function in Drosophila |
| Q50902089 | Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis. |
| Q57341921 | Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β |
| Q41822677 | Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs |
| Q37931062 | Analysis of amyloid precursor protein function in Drosophila melanogaster |
| Q38045853 | Animal models of Alzheimer disease |
| Q34126136 | Animal models of Alzheimer's disease and evaluation of anti-dementia drugs |
| Q24304445 | Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells |
| Q40763877 | Apical sorting of beta-secretase limits amyloid beta-peptide production |
| Q40146627 | Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production |
| Q38493207 | Application of a Bioinformatics-Based Approach to Identify Novel Putative in vivo BACE1 Substrates |
| Q40243417 | Artefactual effects of lipid-based cell transfection reagents on AbetaPP processing and Abeta production |
| Q37755129 | Aspects of beta-amyloid as a biomarker for Alzheimer's disease |
| Q47825157 | Assessing the protease and protease inhibitor content of the human genome. |
| Q46817154 | Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations: meta-analysis including Korean samples |
| Q31123558 | Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent |
| Q89200433 | Autotaxin⁻Lysophosphatidic Acid Signaling in Alzheimer's Disease |
| Q33652469 | Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase |
| Q35142894 | Axonal and Schwann cell BACE1 is equally required for remyelination of peripheral nerves |
| Q37993451 | Aβ toxicity in Alzheimer's disease |
| Q37677861 | AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease |
| Q24336570 | BACE (beta-secretase) modulates the processing of APLP2 in vivo |
| Q37598601 | BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis |
| Q44535324 | BACE-2 is overexpressed in Down's syndrome. |
| Q44686140 | BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes |
| Q34156758 | BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease |
| Q41019229 | BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus. |
| Q47658329 | BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. |
| Q39733952 | BACE1 Inhibitor Peptides: Can an Infinitely Small k cat Value Turn the Substrate of an Enzyme into Its Inhibitor? |
| Q44643912 | BACE1 Suppression by RNA Interference in Primary Cortical Neurons |
| Q93152965 | BACE1 Translation: At the Crossroads Between Alzheimer's Disease Neurodegeneration and Memory Consolidation |
| Q36109558 | BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid. |
| Q33643141 | BACE1 and BACE2 enzymatic activities in Alzheimer's disease |
| Q44346043 | BACE1 and BACE2 in pathologic and normal human muscle |
| Q28257726 | BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease |
| Q35856328 | BACE1 as a potential biomarker for Alzheimer's disease |
| Q38120669 | BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status |
| Q45275672 | BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. |
| Q30495458 | BACE1 deficiency causes altered neuronal activity and neurodegeneration |
| Q44722202 | BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease |
| Q50422623 | BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions |
| Q28307707 | BACE1 expression and activity: relevance in Alzheimer's disease |
| Q35809329 | BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice |
| Q40282792 | BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation |
| Q39705874 | BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease |
| Q34174700 | BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease |
| Q64935542 | BACE1 inhibition as a therapeutic strategy for Alzheimer's disease. |
| Q50074018 | BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology |
| Q38332419 | BACE1 inhibitor drugs in clinical trials for Alzheimer's disease |
| Q36427048 | BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease |
| Q37309641 | BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus |
| Q92287758 | BACE1 partial deletion induces synaptic plasticity deficit in adult mice |
| Q37087903 | BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway |
| Q38964520 | BACE1 regulates the proliferation and cellular functions of Schwann cells. |
| Q30483997 | BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. |
| Q40649318 | BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors |
| Q30496432 | BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization |
| Q33202614 | BACE1: the beta-secretase enzyme in Alzheimer's disease |
| Q38090741 | BACE2 as a new diabetes target: a patent review (2010 - 2012). |
| Q24291363 | BACE2 functions as an alternative alpha-secretase in cells |
| Q46178773 | BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells |
| Q24675964 | BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein |
| Q37785298 | BACE: Therapeutic target and potential biomarker for Alzheimer's disease |
| Q48736362 | BIN1 regulates BACE1 intracellular trafficking and amyloid-β production |
| Q53588736 | Bace1 modulates myelination in the central and peripheral nervous system. |
| Q36089364 | Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease |
| Q42522365 | Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles |
| Q34204313 | Beta-amyloid therapies in Alzheimer's disease |
| Q46980143 | Beta-galactoside alpha2,6-sialyltransferase I cleavage by BACE1 enhances the sialylation of soluble glycoproteins. A novel regulatory mechanism for alpha2,6-sialylation |
| Q44563779 | Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease |
| Q30749785 | Beta-secretase (BACE) as a drug target for Alzheimer's disease |
| Q40542542 | Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling |
| Q34976280 | Beta-secretase as a target for the treatment of Alzheimer's disease |
| Q30497942 | Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice |
| Q47940819 | Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease |
| Q73721783 | Beta-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease |
| Q48217048 | Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis |
| Q44135809 | BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients |
| Q34750587 | Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides |
| Q38122497 | Biological function of Presenilin and its role in AD pathogenesis |
| Q24622136 | Biological markers of amyloid beta-related mechanisms in Alzheimer's disease |
| Q35683767 | Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo |
| Q37715869 | Can BACE1 inhibition mitigate early axonal pathology in neurological diseases? |
| Q53319143 | Cathepsins S, B and L with aminopeptidases display β-secretase activity associated with the pathogenesis of Alzheimer's disease. |
| Q37416750 | Cell biology, regulation and inhibition of beta-secretase (BACE-1). |
| Q33813065 | Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats |
| Q52139105 | Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice. |
| Q44511130 | Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). |
| Q30661499 | Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines. |
| Q42496506 | Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter |
| Q34614786 | Chronic administration of anti-stroke herbal medicine TongLuoJiuNao reduces amyloidogenic processing of amyloid precursor protein in a mouse model of Alzheimer's disease |
| Q37707712 | Chronic treatment with anesthetic propofol attenuates β-amyloid protein levels in brain tissues of aged mice |
| Q28236674 | Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1 |
| Q42443317 | Cloning and expression of the rat BACE1 promoter. |
| Q34286933 | Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease |
| Q42703925 | Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production |
| Q34088442 | Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts |
| Q41762167 | Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5' untranslated region |
| Q92881963 | Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics |
| Q84337420 | Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration |
| Q33929533 | Conservation of the biochemical mechanisms of signal transduction among mammalian Notch family members |
| Q39418939 | Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. |
| Q48394549 | Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase |
| Q97570180 | Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease |
| Q27650198 | Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid Protein Production |
| Q24291219 | Cysteine 73 in bleomycin hydrolase is critical for amyloid precursor protein processing |
| Q35596997 | Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease |
| Q42452241 | Cysteine proteases are the major β‐secretase in the regulated secretory pathway that provides most of the β‐amyloid in Alzheimer's disease: Role of BACE 1 in the constitutive secretory pathway |
| Q38419073 | DC2 and keratinocyte-associated protein 2 (KCP2), subunits of the oligosaccharyltransferase complex, are regulators of the gamma-secretase-directed processing of amyloid precursor protein (APP). |
| Q40755466 | Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein |
| Q40624219 | Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress |
| Q34777681 | Dementia epidemiology |
| Q35048864 | Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. |
| Q93162004 | Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase) |
| Q34082529 | Design, synthesis, and biological evaluation of novel fluorinated ethanolamines. |
| Q53442865 | Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0. |
| Q35940403 | Development of a specific ELISA to measure BACE1 levels in human tissues |
| Q36852202 | Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation |
| Q40504171 | Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme |
| Q27674362 | Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease |
| Q36640414 | Disease modifying therapy for AD? |
| Q40794695 | Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. |
| Q35575845 | Distinct presenilin‐dependent and presenilin‐independent γ‐secretases are responsible for total cellular Aβ production |
| Q34094449 | Divalent cation tolerance protein binds to β-secretase and inhibits the processing of amyloid precursor protein |
| Q35405370 | Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease |
| Q30940227 | Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease |
| Q44597512 | Efficient inhibition of β‐secretase gene expression in HEK293 cells by tRNAVal‐driven and CTE‐helicase associated hammerhead ribozymes |
| Q44658826 | Electrophoretic mobility of Alzheimer’s amyloid-β peptides in urea–sodium dodecyl sulfate–polyacrylamide gel electrophoresis |
| Q35019434 | Emerging Alzheimer's disease therapies: inhibition of beta-secretase |
| Q40674796 | Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation |
| Q30308354 | Endosomal sorting of amyloid precursor protein-P-selectin chimeras influences secretase processing |
| Q34720034 | Endothelial nitric oxide modulates expression and processing of amyloid precursor protein |
| Q46818675 | Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. |
| Q34158282 | Enzymic properties of recombinant BACE2. |
| Q37338606 | ErbB receptors and the development of the nervous system |
| Q47965428 | Ethanol Alters APP Processing and Aggravates Alzheimer-Associated Phenotypes |
| Q34649008 | Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein |
| Q48696412 | Expression Pattern of Scavenger Receptors and Amyloid-β Phagocytosis of Astrocytes and Microglia in Culture are Modified by Acidosis: Implications for Alzheimer's Disease. |
| Q22253458 | Expression analysis of BACE2 in brain and peripheral tissues |
| Q47351612 | Expression of BC1 Impairs Spatial Learning and Memory in Alzheimer's Disease Via APP Translation. |
| Q34092787 | Expression of reticulon 3 in Alzheimer's disease brain. |
| Q42064210 | Fragment Binding to β-Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches |
| Q33862796 | Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects |
| Q40270803 | Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells |
| Q40478080 | Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity. |
| Q40226763 | GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. |
| Q48345479 | GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. |
| Q24336029 | GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-β production |
| Q37394529 | Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. |
| Q37130650 | Gamma-secretase inhibition and modulation for Alzheimer's disease |
| Q34161046 | Gamma-secretase inhibitors and Alzheimer's disease |
| Q27010208 | General anesthetics and β-amyloid protein |
| Q31100408 | Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. |
| Q38559613 | Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site |
| Q43873373 | Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression |
| Q36089357 | Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. |
| Q46398656 | Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese |
| Q28247574 | Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein |
| Q36804954 | Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves |
| Q34509807 | Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics |
| Q34708236 | Genetically engineered mouse models of neurodegenerative diseases |
| Q41875693 | Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase |
| Q45286392 | High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease |
| Q40537045 | Human BACE forms dimers and colocalizes with APP. |
| Q44321200 | Human beta-secretase activity in yeast detected by a novel cellular growth selection system. |
| Q48404141 | Human beta-secretase and Alzheimer's disease |
| Q48091190 | Hypothesis on the relationship between the change in intracellular pH and incidence of sporadic Alzheimer's disease or vascular dementia |
| Q40170530 | Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation |
| Q40210823 | IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes |
| Q37961866 | Identification and biology of β-secretase |
| Q40684851 | Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation |
| Q73235288 | Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates |
| Q30831175 | Identification of beta-secretase-like activity using a mass spectrometry-based assay system |
| Q48194477 | Identification of rare RTN3 variants in Alzheimer's disease in Han Chinese. |
| Q34080500 | In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase |
| Q36100816 | In search of gamma-secretase: presenilin at the cutting edge |
| Q45057180 | In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase |
| Q47280385 | Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to βγ-Secretase-Mediated Processing of the Amyloid-β Protein Precursor: Utility of an AβPP-GAL4 Reporter Assay |
| Q37234006 | Increased expression of reticulon 3 in neurons leads to reduced axonal transport of β site amyloid precursor protein-cleaving enzyme 1. |
| Q33637336 | Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease |
| Q36869427 | Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease |
| Q34007475 | Inhibition of BACE1 for therapeutic use in Alzheimer's disease |
| Q34624551 | Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. |
| Q54199487 | Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein. |
| Q33243260 | Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies |
| Q53447030 | Inhibitory evaluation of sulfonamide chalcones on β-secretase and acylcholinesterase. |
| Q26999922 | Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease |
| Q24300851 | Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme |
| Q40545312 | Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein |
| Q37765478 | Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease |
| Q29615626 | Intracellular amyloid-beta in Alzheimer's disease |
| Q39138637 | Intracellular itinerary of internalised β-secretase, BACE1, and its potential impact on β-amyloid peptide biogenesis. |
| Q37915426 | Intracellular trafficking of the β-secretase and processing of amyloid precursor protein |
| Q37155734 | Intramembrane proteolysis |
| Q35055486 | Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration |
| Q38851332 | Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. |
| Q37781814 | Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions |
| Q30319326 | Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases |
| Q37772582 | Kynurenines, neurodegeneration and Alzheimer's disease |
| Q34355809 | L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells |
| Q42091639 | Leaky scanning and reinitiation regulate BACE1 gene expression |
| Q36576492 | Leptin signaling and Alzheimer's disease |
| Q35103035 | Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma |
| Q34584102 | Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease |
| Q35593014 | Loss of Bace1 in mice does not alter the severity of caerulein induced pancreatitis |
| Q46121560 | Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes |
| Q44529068 | Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice |
| Q36457072 | Lysophosphatidic acid induces increased BACE1 expression and Aβ formation. |
| Q47856616 | MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradation |
| Q33838378 | Mammalian Metallothionein-3: New Functional and Structural Insights |
| Q36600041 | Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease |
| Q37855656 | Mechanisms of neural and behavioral dysfunction in Alzheimer's disease |
| Q28215685 | Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2 |
| Q32063777 | Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation |
| Q39920937 | MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. |
| Q37596385 | MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects |
| Q35194758 | Mild cognitive impairment clinical trials |
| Q34684198 | Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein |
| Q38014896 | Modulating metals as a therapeutic strategy for Alzheimer's disease |
| Q40161850 | Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins |
| Q46158890 | Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo |
| Q36408857 | Molecular rationale for the pharmacological treatment of Alzheimer's disease. |
| Q34371677 | Molecules involved in reactive sprouting in the hippocampus. |
| Q91994595 | Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies |
| Q40014779 | NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. |
| Q28294422 | Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation |
| Q34718255 | Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells |
| Q37584417 | Neurogenesis and Alzheimer's disease: at the crossroads |
| Q36804007 | Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling |
| Q33971290 | Neuronal models to study amyloid precursor protein expression and processing in vitro |
| Q34687686 | Neurons bearing presenilins: weapons for defense or suicide? |
| Q34180114 | Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer's disease |
| Q36575004 | New pathways in drug discovery for Alzheimer's disease |
| Q24290265 | Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing |
| Q38127470 | Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. |
| Q40794453 | Novel functional assay for proteases and modulators. Application in beta-secretase studies |
| Q47589539 | Oligodendrocytes are a novel source of amyloid peptide generation |
| Q53148965 | Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease. |
| Q40199218 | Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo |
| Q39663097 | Overexpression of amyloid beta precursor protein enhances expression and secretion of ST6Gal1 in C2C12 myogenic cell line |
| Q37036247 | Oxidative stress and transcriptional regulation in Alzheimer disease |
| Q38973023 | Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation |
| Q41909132 | Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. |
| Q33947097 | PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling |
| Q47218201 | Palmitate induced C/EBP homologous protein activation leads to NF-κB -mediated increase in BACE1 activity and Amyloid beta genesis. |
| Q40485801 | Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. |
| Q47593479 | Perspectives of Alzheimer's disease treatments |
| Q37763948 | Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease |
| Q43749044 | Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology |
| Q37295067 | Pharmacotherapeutic targets in Alzheimer's disease |
| Q34566556 | Pharmacotheraphy for Alzheimer's disease |
| Q36318080 | Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development |
| Q30486959 | Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis |
| Q47158935 | Physical activity and prevention of Alzheimer's disease |
| Q35079442 | Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis |
| Q33575863 | Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2 |
| Q37961473 | Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin |
| Q34680488 | Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease |
| Q39087660 | Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig. |
| Q34467706 | Positive and negative regulation of APP amyloidogenesis by sumoylation. |
| Q40838000 | Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing. |
| Q53245194 | Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. |
| Q92135579 | Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease |
| Q53232802 | Presenilin mutants subvert chaperone function. |
| Q33944227 | Presenilin, Notch, and the genesis and treatment of Alzheimer's disease |
| Q51800216 | Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin. |
| Q34265143 | Presenilins as therapeutic targets for the treatment of Alzheimer's disease |
| Q37099368 | Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease |
| Q24803627 | Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH |
| Q40539017 | Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. |
| Q33943689 | Prodomain processing of Asp1 (BACE2) is autocatalytic. |
| Q33890347 | Progress in the development of beta-secretase inhibitors for Alzheimer's disease |
| Q39983829 | Promotion of BACE1 mRNA alternative splicing reduces amyloid beta-peptide production |
| Q36300032 | Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease |
| Q36488794 | Protease pathways in peptide neurotransmission and neurodegenerative diseases |
| Q34110227 | Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process |
| Q34498308 | Protein aggregates and dementia: is there a common toxicity? |
| Q34101110 | Protein aggregation diseases: pathogenicity and therapeutic perspectives |
| Q90172885 | Protein-Encoding RNA-to-RNA Information Transfer in Mammalian Cells: Principles of RNA-Dependent mRNA Amplification |
| Q89433901 | Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments |
| Q40524598 | Proteolytic processing of amyloid-beta precursor protein by secretases does not require cell surface transport |
| Q44642575 | Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets |
| Q28069428 | Proteomic Substrate Identification for Membrane Proteases in the Brain |
| Q89530542 | Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain |
| Q44489634 | Quantification and distribution of beta-secretase alternative splice variants in the rat and human brain |
| Q35166518 | RIPped out by presenilin-dependent gamma-secretase |
| Q40196139 | RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation |
| Q40460851 | RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. |
| Q36444486 | RNAi-mediated knock-down of Dab and Numb attenuate Aβ levels via γ-secretase mediated APP processing |
| Q33926137 | RTN/Nogo in forming Alzheimer's neuritic plaques |
| Q48260013 | Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization |
| Q38185273 | Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral. |
| Q40629788 | Recombinant insect cell expression and purification of human beta-secretase (BACE-1) for X-ray crystallography |
| Q37344787 | Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites |
| Q46157365 | Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis |
| Q34061109 | Regulation of APP cleavage by alpha-, beta- and gamma-secretases |
| Q36645356 | Regulation of global gene expression and cell proliferation by APP |
| Q37794788 | Regulation of β cleavage of amyloid precursor protein |
| Q37961881 | Regulation of β-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer's disease |
| Q34026309 | Remarkable roles of proteolysis on and beyond the cell surface |
| Q52583319 | Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. |
| Q55428413 | Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease. |
| Q47942690 | Resveratrol for Alzheimer's disease |
| Q28275098 | Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation |
| Q36788760 | Reversing hypomyelination in BACE1-null mice with Akt-DD overexpression |
| Q37972068 | Road to Alzheimer's disease: the pathomechanism underlying |
| Q27675616 | Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor |
| Q41555225 | Role of BACE1 in Alzheimer's synaptic function. |
| Q48451687 | Screening a series of sialyltransferases for possible BACE1 substrates |
| Q34536036 | Secretases as targets for drug design in Alzheimer's disease |
| Q34046308 | Secretases as targets for the treatment of Alzheimer's disease |
| Q34284352 | Secretases as therapeutic targets for the treatment of Alzheimer's disease |
| Q37316706 | Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. |
| Q34750660 | Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins |
| Q34932013 | Serpinopathies and the conformational dementias |
| Q51935815 | Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer's disease. |
| Q40330052 | Sialylation enhances the secretion of neurotoxic amyloid-beta peptides |
| Q24656147 | Signaling effect of amyloid-beta(42) on the processing of AbetaPP |
| Q33714700 | Single-nucleotide polymorphisms are associated with cognitive decline at Alzheimer's disease conversion within mild cognitive impairment patients |
| Q38003497 | Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). |
| Q38121847 | Soluble amyloid precursor protein 770 is a novel biomarker candidate for acute coronary syndrome |
| Q40219967 | Solution studies and structural model of the extracellular domain of the human amyloid precursor protein |
| Q44411872 | Specific BACE1 genotypes provide additional risk for late‐onset alzheimer disease in APOE ε4 carriers |
| Q38059094 | Splice variants of the Alzheimer's disease beta-secretase, BACE1. |
| Q44020806 | Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas |
| Q26740189 | Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs |
| Q34342498 | Strategies for disease modification in Alzheimer's disease |
| Q42785839 | Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP. |
| Q37030825 | Structure-activity relationship of memapsin 2: implications on physiological functions and Alzheimer's disease |
| Q31032457 | Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases |
| Q35758963 | Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice. |
| Q37875108 | Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. |
| Q45076875 | Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice |
| Q44573728 | Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies |
| Q34405667 | Targeting the β secretase BACE1 for Alzheimer's disease therapy |
| Q34792043 | Targets for AD treatment: conflicting messages from γ-secretase inhibitors |
| Q36042072 | The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system |
| Q24600203 | The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif |
| Q36397690 | The Alzheimer's disease beta-secretase enzyme, BACE1. |
| Q39755143 | The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. |
| Q35717366 | The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb |
| Q22000600 | The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid |
| Q37108142 | The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease |
| Q35656834 | The Golgi-Localized γ-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-β Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1) |
| Q35659159 | The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning? |
| Q37987919 | The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond |
| Q39095782 | The Metalloprotease Meprin β Is an Alternative β-Secretase of APP. |
| Q34116345 | The Role of presenilins in gamma-secretase activity |
| Q45901500 | The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. |
| Q34014324 | The aging process: where are the drug opportunities? |
| Q29614972 | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics |
| Q78032051 | The amyloid precursor protein interacts with neutral lipids |
| Q44283389 | The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer's disease |
| Q28138194 | The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation |
| Q37614747 | The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential |
| Q32061148 | The beta-secretase, BACE: a prime drug target for Alzheimer's disease |
| Q34398091 | The cell biology of Alzheimer's disease: uncovering the secrets of secretases |
| Q33961288 | The cholinergic neuronal phenotype in Alzheimer's disease |
| Q35549855 | The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis |
| Q28238581 | The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity |
| Q39665687 | The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing |
| Q38184783 | The dark sides of amyloid in Alzheimer's disease pathogenesis |
| Q36332669 | The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors |
| Q53341998 | The genetic association between Cathepsin D and Alzheimer's disease. |
| Q36447798 | The involvement of lipid rafts in Alzheimer's disease |
| Q36113757 | The keystone of Alzheimer pathogenesis might be sought in Aβ physiology |
| Q37845036 | The many substrates of presenilin/γ-secretase |
| Q34190161 | The multiple paradoxes of presenilins |
| Q36122127 | The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo |
| Q21195685 | The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice |
| Q28610071 | The normal and pathologic roles of the Alzheimer's β-secretase, BACE1 |
| Q46244313 | The past, present, and future of disease-modifying therapies for Alzheimer's disease. |
| Q27697610 | The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans |
| Q45299820 | The potential of BACE inhibitors for Alzheimer's therapy |
| Q40534733 | The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease |
| Q34071523 | The processing and biological function of the human amyloid precursor protein (APP): lessons from different cellular models |
| Q28543122 | The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation |
| Q35540369 | The risk of dementia in relation to statins and other lipid lowering agents. |
| Q37474466 | The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease |
| Q37880157 | The role of IL-15 in central nervous system disorders |
| Q37225050 | The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology |
| Q47296419 | The role of astrocytes in amyloid production and Alzheimer's disease |
| Q39671445 | The role of low-density receptor-related protein 1 (LRP1) as a competitive substrate of the amyloid precursor protein (APP) for BACE1 |
| Q34190152 | The role of presenilins in gamma-secretase activity: catalyst or cofactor? |
| Q35107623 | The secretases of Alzheimer's disease |
| Q33887222 | The secretases: enzymes with therapeutic potential in Alzheimer disease |
| Q24291471 | The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate |
| Q28268311 | The ubiquitin-proteasome system in Alzheimer's disease |
| Q53238061 | The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. |
| Q37884646 | The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease |
| Q34014330 | Therapeutic approaches to Alzheimer's disease. |
| Q34988224 | Therapeutic strategies for Alzheimer's disease |
| Q43715378 | Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production |
| Q27002018 | Toward the structure of presenilin/γ-secretase and presenilin homologs |
| Q38062499 | Transcriptional and post-transcriptional regulation of β-secretase. |
| Q40581861 | Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. |
| Q40102571 | Transcriptome Analysis of Sclerotinia sclerotiorum at Different Infection Stages on Brassica napus |
| Q53341822 | Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. |
| Q37520346 | Translational regulation of BACE-1 expression in neuronal and non-neuronal cells |
| Q34079586 | Treatment of Alzheimer's disease: rationale and strategies |
| Q38040990 | Treatment strategies targeting amyloid β-protein |
| Q90965600 | Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden |
| Q34431390 | Two novel DNA motifs are essential for BACE1 gene transcription |
| Q47406803 | Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer’s disease |
| Q36642766 | Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease |
| Q37387103 | Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease |
| Q38984026 | Upregulation of SET expression by BACE1 and its implications in Down syndrome |
| Q35670733 | VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. |
| Q24290528 | X11 alpha and x11 beta interact with presenilin-1 via their PDZ domains |
| Q44225451 | alpha- and beta-secretase: profound changes in Alzheimer's disease. |
| Q34193248 | beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease |
| Q37215845 | beta-Secretase as a therapeutic target for Alzheimer's disease |
| Q33762857 | beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. |
| Q43823461 | beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations |
| Q28345657 | beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging |
| Q35103410 | beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice |
| Q35140078 | gamma-Secretase inhibitors--from molecular probes to new therapeutics? |
| Q34609917 | gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? |
| Q44241753 | gamma-Secretase: characterization and implication for Alzheimer disease therapy |
| Q99711706 | miR-149-5p inhibition reduces Alzheimer's disease β-amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8 |
| Q40174843 | p53-Dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity |
| Q36420889 | pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition |
| Q64892700 | pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo. |
| Q34240868 | Β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis |
| Q36951145 | β-Secretase: its biology as a therapeutic target in diseases |
| Q35821455 | β-Secretases, Alzheimer's Disease, and Down Syndrome |
| Q36385744 | β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects |
| Q37606656 | β-secretase cleavage of the fly amyloid precursor protein is required for glial survival |
| Q28245473 | β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease |
| Q33947055 | β-site amyloid precursor protein cleaving enzyme 1(BACE1) regulates Notch signaling by controlling the cleavage of Jagged 1 (Jag1) and Jagged 2 (Jag2) proteins |
| Q35071626 | γ-Secretase processing and effects of γ-secretase inhibitors and modulators on long Aβ peptides in cells |
Search more.